An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated ( gBRCA m) platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Drew, Y.; de Jonge, M.; Hong, S.H.; Park, Y.H.; Wolfer, A.; Brown, J.; Ferguson, M.; Gore, M.E.; Alvarez, R.H.; Gresty, C.; Angell, H.; Meyer, K.; Learoyd, M.; Tang, M.; Lanasa, M.; Herbolsheimer, P.; Domchek, S.M.

doi:10.1016/j.ygyno.2018.04.555

Cited by 131PARP inhibition in cancer therapyBRCA gene mutations in cancerOvarian cancer diagnosis and treatment

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated ( gBRCA m) platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Drew, Y., de Jonge, M., Hong, S.H., Park, Y.H., Wolfer, A., Brown, J., Ferguson, M., Gore, M.E. +9 more·2018·Gynecologic Oncology

DOI 10.1016/j.ygyno.2018.04.555

Open this paper in CoChat — free account

Integrity signals

Registry

Crossref · 10.1016/j.ygyno.2018.04.555

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The olaparib and durvalumab arm had a higher ORR than that reported for PARPi treatment in germline BRCA-mutated platinum-sensitive relapsed ovarian cancer.
“Besides, olaparib and durvalumab arm also had a higher ORR than that reported for PARPi treatment in germline BRCA-mutated platinum-sensitive relapsed ovarian cancer [229].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [229]

Sorted by citations

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445 · see citing works
Treatment of epithelial ovarian cancer
Kuroki, L. M., & Guntupalli, S. R. (2020) · BMJ · doi:10.1136/bmj.m3773 · Cited by 887 · see citing works
Exploring and comparing adverse events between PARP inhibitors
Lafargue, C. J., Molin, G. Z. D., Sood, A. K., & Coleman, R. L. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30786-1 · Cited by 496 · see citing works
The Immunoscore: Colon Cancer and Beyond
Angell, H. K., Bruni, D., Barrett, J. C., Herbst, R., & Galon, J. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1851 · Cited by 384 · see citing works
Self-citation
Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant
Yang, C. Q., Xia, B.-R., Zhang, Z.-C., Zhang, Y., Lou, G., & Jin, W. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.577869 · Cited by 354 · see citing works
“The phase I/II basket MEDIOLA trial demonstrated that olaparib in combination with an anti–PDL1 antibody, durvalumab, for the treatment of germline BRCA 1/ 2 mutations that were platinum-sensitive resulted in relapse of ovarian cancer (116).”
Background
PARP Inhibitors: Extending Benefit Beyond BRCA -Mutant Cancers
Pilie, P. G., Gay, C. M., Byers, L. A., O’Connor, M. J., & Yap, T. A. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0968 · Cited by 334 · see citing works
Development of PARP and immune-checkpoint inhibitor combinations
Stewart, R. A., Pilié, P. G., & Yap, T. A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-2652 · Cited by 239 · see citing works
Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
Peyraud, F., & Italiano, A. (2020) · Cancers · doi:10.3390/cancers12061502 · Cited by 240 · see citing works
Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer
Liu, J. F., Herold, C. I., Gray, K. P., Penson, R. T., Horowitz, N. S., Konstantinopoulos, P. A., Castro, C. M., Hill, S. J., Curtis, J. D., Luo, W., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.3343 · Cited by 223 · see citing works
Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase II study
Lampert, E. J., Zimmer, A., Padget, M., Cimino-Mathews, A., Nair, J. R., Liu, Y., Swisher, E. M., Hodge, J. W., Nixon, A. B., Nichols, E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0056 · Cited by 220 · see citing works
PARP inhibitors in ovarian cancer
Franzese, E., Centonze, S., Diana, A., Carlino, F., Guerrera, L. P., Napoli, M. D., Vita, F. D., Pignata, S., Ciardiello, F., & Orditura, M. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.12.002 · Cited by 214 · see citing works
Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy
Gourley, C., Balmañà, J., Ledermann, J. A., Serra, V., Dent, R. A., Loibl, S., Pujade-Lauraine, É., & Boulton, S. J. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02050 · Cited by 193 · see citing works
PARP Inhibition in Cancer: An Update on Clinical Development
Sachdev, E., Tabatabai, R., Roy, V. Y., Rimel, B. J., & Mita, M. M. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00680-2 · Cited by 184 · see citing works
The DNA Damaging Revolution: PARP Inhibitors and Beyond
Yap, T. A., Plummer, R., Azad, N. S., & Helleday, T. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_238473 · Cited by 175 · see citing works
Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors
Vikas, P., Borcherding, N., Chennamadhavuni, A., & Garje, R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00570 · Cited by 179 · see citing works
PARP inhibitors: enhancing efficacy through rational combinations
Bhamidipati, D., Haro-Silerio, J. I., Yap, T. A., & Ngoi, N. Y. L. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02326-7 · Cited by 179 · see citing works
Ovarian Cancer Immunotherapy: Turning up the Heat
Ghisoni, E., Imbimbo, M., Zimmermann, S., & Valabrega, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20122927 · Cited by 161 · see citing works
Prospects for combining immune checkpoint blockade with PARP inhibition
Li, A., Yi, M., Qin, S., Chu, Q., Luo, S., & Wu, K. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0784-8 · Cited by 143 · see citing works
Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
Boussios, S., Abson, C., Moschetta, M., Rassy, E., Karathanasi, A., Bhat, T., Ghumman, F. I. A., Sheriff, M., & Pavlidis, N. A. (2020) · Drugs in R&D · doi:10.1007/s40268-020-00301-8 · Cited by 140 · see citing works
Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review
Boussios, S., Karihtala, P., Moschetta, M., Karathanasi, A., Sadauskaite, A., Rassy, E., & Pavlidis, N. A. (2019) · Diagnostics · doi:10.3390/diagnostics9030087 · Cited by 128 · see citing works
New strategies in ovarian cancer treatment
Lee, J., Minasian, L. M., & Kohn, E. C. (2019) · Cancer · doi:10.1002/cncr.32544 · Cited by 122 · see citing works
Immunotherapy in Ovarian Cancer: Are We There Yet?
Kandalaft, L. E., Odunsi, K. O., & Coukos, G. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00508 · Cited by 123 · see citing works
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses
Zimmer, A. S., Nichols, E. H., Cimino‐Mathews, A., Peer, C. J., Cao, L., Lee, M.-J., Kohn, E. C., Annunziata, C. M., Lipkowitz, S., Trepel, J. B., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0680-3 · Cited by 114 · see citing works
PARP Inhibitors in Cancer Diagnosis and Therapy
Chan, C. Y., Tan, K. V., & Cornelissen, B. T. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2766 · Cited by 109 · see citing works
“Olaparib þ durvalumab þ bevacizumab I/II MEDIOLA Advanced or metastatic solid tumor, irrespective of gBRCA1/2 status BRACAnalysis or myChoice assay (Myriad Genetics), HRD score undetermined NCT02734004 Active, not recruiting (50)”
Background
Targeting the immune microenvironment for ovarian cancer therapy
Blanc‐Durand, F., Xian, L. C. W., & Tan, D. S. P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1328651 · Cited by 110 · see citing works
Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives
Borella, F., Ghisoni, E., Giannone, G., Cosma, S. D., Benedetto, C., Valabrega, G., & Katsaros, D. (2020) · Diagnostics · doi:10.3390/diagnostics10030146 · Cited by 94 · see citing works
Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms
Jain, A., Barge, A., & Parris, C. N. (2024) · Oncogene · doi:10.1038/s41388-024-03227-6 · Cited by 100 · see citing works
Combined PARP and Immune Checkpoint Inhibition in Ovarian Cancer
Lee, E. K., & Konstantinopoulos, P. A. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.06.004 · Cited by 89 · see citing works
Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
Madariaga, A., Bowering, V. L., Ahrari, S., Oza, A. M., & Lheureux, S. (2020) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2020-001288 · Cited by 86 · see citing works
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study
Drew, Y., Kim, J., Penson, R. T., O’Malley, D. M., Parkinson, C., Roxburgh, P., Plummer, R., Im, S., Imbimbo, M., Ferguson, M., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2249 · Cited by 89 · see citing works
Self-citation
Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives
Maiorano, B. A., Maiorano, M. F. P., Lorusso, D., & Maiello, E. (2021) · Cancers · doi:10.3390/cancers13174438 · Cited by 84 · see citing works
“Since BRCA mutation and HRD have been proposed to correlate with platinum sensitivity in contemporary deficient nucleotide excision repair, the co-administration of PARPis and ICIs in PS-ROC could result in higher ORR and survival rates [29-31].”
BackgroundInfluential
Role of Immunotherapy in Breast Cancer
Jacob, S. L., Huppert, L. A., & Rugo, H. S. (2023) · JCO Oncology Practice · doi:10.1200/op.22.00483 · Cited by 79 · see citing works
Current Ovarian Cancer Maintenance Strategies and Promising New Developments
Gogineni, V., Morand, S. M., Staats, H., Royfman, R., Devanaboyina, M., Einloth, K. R., Dever, D., Stanbery, L., Aaron, P. A., Manning, L., et al. (2020) · Journal of Cancer · doi:10.7150/jca.49406 · Cited by 77 · see citing works
Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches
Palaia, I., Tomao, F., Sassu, C. M., Musacchio, L., & Panici, P. B. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s205950 · Cited by 83 · see citing works
Wise Management of Ovarian Cancer: On the Cutting Edge
Boussios, S., Mikropoulos, C., Samartzis, E. P., Karihtala, P., Moschetta, M., Sheriff, M., Karathanasi, A., Sadauskaite, A., Rassy, E., & Pavlidis, N. A. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10020041 · Cited by 73 · see citing works
Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations
Madariaga, A., Lheureux, S., & Oza, A. M. (2019) · Cancers · doi:10.3390/cancers11030416 · Cited by 72 · see citing works
The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors
Wu, Z., Cui, P., Tao, H., Zhang, S., Ma, J., Liu, Z., Wang, J., Qian, Y., Chen, S., Huang, Z., et al. (2021) · Clinical Medicine Insights Oncology · doi:10.1177/1179554921996288 · Cited by 71 · see citing works
The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers
Zhu, L., Liu, J., Chen, J., & Zhou, Q. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01218-8 · Cited by 69 · see citing works
Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations
Veneris, J. T., Matulonis, U. A., Liu, J. F., & Konstantinopoulos, P. A. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.09.021 · Cited by 62 · see citing works
Infiltration by CXCL10 Secreting Macrophages Is Associated With Antitumor Immunity and Response to Therapy in Ovarian Cancer Subtypes
Ardighieri, L., Missale, F., Bugatti, M., Gatta, L. B., Pezzali, I., Monti, M., Gottardi, S., Zanotti, L., Bignotti, E., Ravaggi, A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.690201 · Cited by 61 · see citing works
“However, the recent combination of ICIs and PARPi provided better results (11, 47).”
Background
PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer
Post, C., Westermann, A. M., Bosse, T., Creutzberg, C. L., & Kroep, J. R. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102973 · Cited by 63 · see citing works
“Five patients discontinued olaparib and three discontinued durvalumab due to an adverse event (Drew et al., 2018, 2019).”
Integrating Immunotherapy and Targeted Therapy in Cancer Treatment: Mechanistic Insights and Clinical Implications
Bergholz, J. S., Wang, Q., Kabraji, S. K., & Zhao, J. J. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2300 · Cited by 61 · see citing works
MEK Inhibition Remodels the Immune Landscape of Mutant <i>KRAS</i> Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors
Yang, B., Li, X., Fu, Y., Guo, E., Ye, Y., Li, F., Liu, S., Xiao, R., Liu, C., Lu, F., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2370 · Cited by 55 · see citing works
“gov) with four different PARPi/anti–PD-1/L1 combinations being tested: olaparib/ durvalumab (10, 11), niraparib/pembrolizumab (12), talazoparib/ avelumab (13, 14), and BGB-A317/BGB-290 (15).”
PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies
Miller, R. E., El-Shakankery, K. H., & Lee, J. (2022) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2022.33.e44 · Cited by 54 · see citing works
Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer
Kurnit, K. C., Coleman, R. L., & Westin, S. N. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0572-7 · Cited by 54 · see citing works
Combination Immune Checkpoint Blockade Strategies to Maximize Immune Response in Gynecological Cancers
Liu, Y. L., & Zamarin, D. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0740-8 · Cited by 53 · see citing works
PARP Inhibitors in Breast and Ovarian Cancer
Wang, S. S. Y., Jie, Y. E., Cheng, S. W., Ling, G. L., & Heong, V. Y. M. (2023) · Cancers · doi:10.3390/cancers15082357 · Cited by 60 · see citing works
Immunotherapy with checkpoint inhibitors in patients with ovarian cancer: Still promising?
González-Martı́n, A., & Sánchez‐Lorenzo, L. (2019) · Cancer · doi:10.1002/cncr.32520 · Cited by 51 · see citing works
Driving Immune Responses in the Ovarian Tumor Microenvironment
Ning, F., Cole, C. B., & Annunziata, C. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.604084 · Cited by 51 · see citing works
Immune Therapy Opportunities in Ovarian Cancer
Kandalaft, L. E., Odunsi, K. O., & Coukos, G. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280539 · Cited by 50 · see citing works
Management and Treatment of Recurrent Epithelial Ovarian Cancer
Armbruster, S. D., Coleman, R. L., & Rauh‐Hain, J. A. (2018) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.07.005 · Cited by 50 · see citing works
Recent advancements in PARP inhibitors-based targeted cancer therapy
Zhou, P., Wang, J. L., Mishail, D., & Wang, C. (2020) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbaa030 · Cited by 50 · see citing works
Therapeutic applications of PARP inhibitors in ovarian cancer
Xie, H., Wang, W., Xia, B., Jin, W., & Lou, G. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110204 · Cited by 45 · see citing works
PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives
Musacchio, L., Caruso, G., Pisano, C., Cecere, S. C., Napoli, M. D., Attademo, L., Tambaro, R., Russo, D., Califano, D., Palaia, I., et al. (2020) · Cancer Management and Research · doi:10.2147/cmar.s221001 · Cited by 47 · see citing works
Overview of Immune Checkpoint Inhibitors in Gynecological Cancer Treatment
Pirš, B., Škof, E., Smrkolj, V., & Smrkolj, Š. (2022) · Cancers · doi:10.3390/cancers14030631 · Cited by 46 · see citing works
The potential of PARP inhibitors in targeted cancer therapy and immunotherapy
Hunia, J., Gawalski, K., Szredzka, A., Suskiewicz, M. J., & Nowis, D. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1073797 · Cited by 45 · see citing works
Major clinical research advances in gynecologic cancer in 2018
Kim, M., Suh, D. H., Lee, K.-H., Eom, K., Toftdahl, N. G., Mirza, M. R., & Kim, J. (2019) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2019.30.e18 · Cited by 43 · see citing works
PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations
Vanacker, H., Harter, P., Labidi‐Galy, S. I., Banerjee, S. N., Oaknin, A., Lorusso, D., & Ray-Coquard, I. L. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102255 · Cited by 45 · see citing works
PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data
Moutafi, M. K., Economopoulou, P., Rimm, D. L., & Psyrri, A. K. (2021) · Oral Oncology · doi:10.1016/j.oraloncology.2021.105292 · Cited by 44 · see citing works
Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune Checkpoints
Franzese, O., & Graziani, G. (2022) · Cancers · doi:10.3390/cancers14225633 · Cited by 41 · see citing works
Immunotherapy in breast cancer: current landscape and emerging trends
Ran, R., Chen, X., Yang, J., & Xu, B. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00667-y · Cited by 45 · see citing works
“Preclinical data indicated that PARP inhibitors may stimulate the host antitumor immune responses by generating neoantigens by DNA damage, upregulating interferon synthesis via the STING pathway, and augmenting PD-L1 expression [146, 147].”
Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy
Gou, R., Dong, H., & Lin, B. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118434 · Cited by 40 · see citing works
The DNA damage response network in the treatment of head and neck squamous cell carcinoma
Psyrri, A. K., Gkotzamanidou, M. A., Papaxoinis, G., Krikoni, L., Economopoulou, P., Kotsantis, I., Anastasiou, Μ., & Souliotis, V. L. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100075 · Cited by 41 · see citing works
Targeting PARP1 to Enhance Anticancer Checkpoint Immunotherapy Response: Rationale and Clinical Implications
Wanderley, C. W. S., Corrêa, T. S., Scaranti, M., Cunha, F. Q., & Barroso‐Sousa, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.816642 · Cited by 40 · see citing works
Immunotherapy in Ovarian Cancer
Wang, W., Liu, J. R., & Zou, W. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.02.002 · Cited by 36 · see citing works
Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises
Pham, M. M., Ngoi, N. Y. L., Peng, G., Tan, D. S. P., & Yap, T. A. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.05.004 · Cited by 37 · see citing works
Lactobacillus reuteri Releasing IL-22 (LR-IL-22) Facilitates Intestinal Radioprotection for Whole-Abdomen Irradiation (WAI) of Ovarian Cancer
Hamade, D. F., Espinal, A., Yu, J., Leibowitz, B. J., Fisher, R., Hou, W., Shields, D., van Pijkeren, J.-P., Mukherjee, A., Epperly, M. W., et al. (2022) · Radiation Research · doi:10.1667/rade-21-00224.1 · Cited by 36 · see citing works
Research Progress of PARP Inhibitor Monotherapy and Combination Therapy for Endometrial Cancer
Shen, K., Yang, L., Li, F., Zhang, F., Ding, L., Yang, J., Lu, J., Wang, N., & Wang, Y. (2021) · Current Drug Targets · doi:10.2174/1389450122666210617111304 · Cited by 33 · see citing works
Immunotherapy in ovarian cancer: fake news or the real deal?
Marth, C., Wieser, V. E., Tsibulak, I., & Zeimet, A. G. (2019) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2018-000011 · Cited by 35 · see citing works
Targeting DNA Damage Response and Repair Genes to Enhance Anticancer Immunotherapy: Rationale and Clinical Implication
Lamberti, G., Andrini, E., Sisi, M., Federico, A. D., & Ricciuti, B. (2020) · Future Oncology · doi:10.2217/fon-2020-0215 · Cited by 34 · see citing works
Targeting PD-1/PD-L1 axis as new horizon for ovarian cancer therapy
Khatoon, E., Parama, D., Kumar, A., Alqahtani, M. S., Abbas, M. A. E., Girisa, S., Sethi, G., & Kunnumakkara, A. B. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120827 · Cited by 34 · see citing works
Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy
Schepisi, G., Casadei, C., Toma, I., Poti, G., Iaia, M. L., Farolfi, A., Conteduca, V., Lolli, C., Ravaglia, G., Brighi, N., et al. (2021) · Cancers · doi:10.3390/cancers13040840 · Cited by 30 · see citing works
DNA damage response and PD-1/PD-L1 pathway in ovarian cancer
Zhang, T., Zheng, S., Yang, L., Li, X., Wu, J., Sun, Y., & Liu, G. (2021) · DNA repair · doi:10.1016/j.dnarep.2021.103112 · Cited by 27 · see citing works
Evolving Concepts in the Management of Newly Diagnosed Epithelial Ovarian Cancer
Gourley, C., & Bookman, M. A. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00337 · Cited by 25 · see citing works
PARP Inhibitors in Gynecologic Cancers: What Is the Next Big Development?
Lightfoot, M. D. S., Montemorano, L., & Bixel, K. L. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-0873-4 · Cited by 25 · see citing works
Combination Treatment Strategies to Overcome PARP Inhibitor Resistance
Soung, Y. H., & Chung, J. (2023) · Biomolecules · doi:10.3390/biom13101480 · Cited by 27 · see citing works
“Patients received 300 mg of Olaparib twice daily for 4 weeks, followed by a combination of Olaparib (300 mg) and Durvalumab (1.5 g) until tumor progression was observed [80].”
MethodInfluential
Effective antitumor activity of 5T4‐specific CAR‐T cells against ovarian cancer cells in vitro and xenotransplanted tumors in vivo
Guo, C., Dong, E., Lai, Q., Zhou, S., Zhang, G., Wu, M., Yue, X., Tao, Y., Peng, Y., Ali, J., et al. (2020) · MedComm · doi:10.1002/mco2.34 · Cited by 24 · see citing works
Interleukin-6 Is a Crucial Factor in Shaping the Inflammatory Tumor Microenvironment in Ovarian Cancer and Determining Its Hot or Cold Nature with Diagnostic and Prognostic Utilities
Amer, H., Flanagan, K. L., Kampan, N. C., Itsiopoulos, C., Scott, C. L., Kartikasari, A. E. R., & Plebanski, M. (2025) · Cancers · doi:10.3390/cancers17101691 · Cited by 27 · see citing works
“For example, a Phase II trial led by Drew et al. explored the combination of durvalumab (an anti-PD1 agent) with Olaparib (a PARP inhibitor) in OC patients who were platinum-sensitive and had a BRCA mutation [202].”
Release of Interferon-β (IFN-β) from Probiotic Limosilactobacillus reuteri-IFN-β (LR-IFN-β) Mitigates Gastrointestinal Acute Radiation Syndrome (GI-ARS) following Whole Abdominal Irradiation
Hamade, D. F., Epperly, M. W., Fisher, R., Hou, W., Shields, D. S., van Pijkeren, J., Mukherjee, A., Yu, J., Leibowitz, B. J., Vlad, A., et al. (2023) · Cancers · doi:10.3390/cancers15061670 · Cited by 21 · see citing works
The Perfect Combination: Enhancing Patient Response to PD-1-Based Therapies in Epithelial Ovarian Cancer
James, N. E., Woodman, M. F., DiSilvestro, P., & Ribeiro, J. R. (2020) · Cancers · doi:10.3390/cancers12082150 · Cited by 19 · see citing works
Patient Assessment and Therapy Planning Based on Homologous Recombination Repair Deficiency
Li, W., Gao, L., Yi, X., Shi, S., Huang, J., Shi, L. M., Zhou, X., Wu, L., & Ying, J. (2023) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2023.02.004 · Cited by 19 · see citing works
An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3045), AMBITION
Lee, J., Yi, J. Y., Kim, H. S., Lim, J. H.-J., Kim, S., Nam, B., Kim, H. S., Kim, J., Choi, C. H., Kim, B., et al. (2019) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyz085 · Cited by 18 · see citing works
Targeting DNA Repair Response Promotes Immunotherapy in Ovarian Cancer: Rationale and Clinical Application
Xie, H., Wang, W., Qi, W.-C., Jin, W., & Xia, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.661115 · Cited by 17 · see citing works
“In the phase II study involving 32 patients with germline BRCA1/2 mutant platinum-sensitive ovarian cancer, the disease control rate (DCR) at 12 weeks was 81%, and the objective response rate (ORR) was 63%, with acceptable toxicity (85).”
Background
Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors
Lee, E. K., & Matulonis, U. A. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1773791 · Cited by 16 · see citing works
Are antiangiogenics a good ‘partner’ for immunotherapy in ovarian cancer?
García-Martínez, E., Redondo, A., Piulats, J. M., Garzotto, A. A. R., & Casado, A. (2020) · Angiogenesis · doi:10.1007/s10456-020-09734-w · Cited by 15 · see citing works
Understanding genetic determinants of resistance to immune checkpoint blockers
Aspeslagh, S., Chabanon, R. M., Champiat, S., & Postel-Vinay, S. C. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.020 · Cited by 15 · see citing works
Strategies for the prevention or reversal of PARP inhibitor resistance
Mitri, Z. I., Goodyear, S. M., & Mills, G. B. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2393251 · Cited by 15 · see citing works
Management and clinical outcomes of patients with recurrent/progressive ovarian clear cell carcinoma
Huang, H.-J., Yang, L., Tung, H., Ku, F.-C., Wu, R., Tang, Y., Chang, W., Jung, S., Wang, C., Lin, C., et al. (2019) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2019.11.018 · Cited by 14 · see citing works
PARP inhibition in the ovarian cancer patient: Current approvals and future directions
Kurnit, K. C., Avila, M., Hinchcliff, E., Coleman, R. L., & Westin, S. N. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107588 · Cited by 15 · see citing works
Combined PARP and Dual Topoisomerase Inhibition Potentiates Genome Instability and Cell Death in Ovarian Cancer
Flörkemeier, I., Hillmann, J. S., Weimer, J. P., Hildebrandt, J., Hedemann, N., Rogmans, C., Dempfle, A., Arnold, N., Clement, B., & Bauerschlag, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810503 · Cited by 13 · see citing works
PARP Inhibition Combined with Immune Checkpoint Blockade in SCLC: Oasis in an Immune Desert or Mirage?
Gay, C. M., & Byers, L. A. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.05.004 · Cited by 13 · see citing works
Immunotherapies in ovarian cancer
García-Martínez, E., & Fidalgo, J. A. P. (2020) · European Journal of Cancer Supplements · doi:10.1016/j.ejcsup.2020.02.002 · Cited by 13 · see citing works
BRCA mutations in pancreatic cancer and progress in their targeting
Alkassis, S., Yazdanpanah, O., & Philip, P. A. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1957462 · Cited by 12 · see citing works
Current and future landscape of poly (ADP-ribose) polymerase inhibition resistance
Hinchcliff, E., Chelariu-Raicu, A., & Westin, S. N. (2020) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000678 · Cited by 12 · see citing works
Chemotherapy-free treatment of recurrent advanced ovarian cancer: myth or reality?
Marques, C., da Silva, F. F., Sousa, I., & Nave, M. (2022) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2022-003719 · Cited by 11 · see citing works
Preclinical and Clinical Immunotherapeutic Strategies in Epithelial Ovarian Cancer
Martínez, A., Delord, J., Ayyoub, M., & Devaud, C. (2020) · Cancers · doi:10.3390/cancers12071761 · Cited by 11 · see citing works
Beyond monotherapy: An era ushering in combinations of PARP inhibitors with immune checkpoint inhibitors for solid tumors
Zhou, L., Wan, Y., Zhang, L., Meng, H., Yuan, L., Zhou, S., Cheng, W., & Jiang, Y. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116733 · Cited by 10 · see citing works
A case report of a dramatic response to olaparib in a patient with metastatic pancreatic cancer harboring a germline BRCA2 mutation
Wang, H., Mao, C., Li, N., Sun, L., Zheng, Y., & Xu, N. (2019) · Medicine · doi:10.1097/md.0000000000017443 · Cited by 10 · see citing works
Update in the use and evaluation of poly (ADP-ribose) polymerase inhibitors in epithelial ovarian cancer: current and pending clinical research
Washington, C. R., Gunderson, C. C., & Moore, K. N. (2018) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000507 · Cited by 9 · see citing works
The distinct landscape of tumor immune microenvironment in homologous recombination deficient cancers
Xu, Q., Wen, Y., Huang, T., Li, H., Liu, X., Shi, S.-N., Gong, W., Mills, G. B., Ma, D., Gao, Q., et al. (2025) · Biomarker Research · doi:10.1186/s40364-025-00814-x · Cited by 10 · see citing works

Clinical trial protocol1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer
Wethington, S. L., Shah, P. D., Martin, L. P., et al. (2023) · doi:10.1158/1078-0432.23814207.v1
Self-citation
Clinical trial protocol1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer
Wethington, S. L., Shah, P. D., Martin, L. P., et al. (2023) · doi:10.1158/1078-0432.23814207
Self-citation
Supplementary Figure 1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer
Wethington, S. L., Shah, P. D., Martin, L. P., et al. (2023) · doi:10.1158/1078-0432.23814204.v1
Self-citation
High-Grade Carcinomas, BRCA Mutations and the Role of PARP Inhibitors
Ledermann, J. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-32110-3_12
Abstract CT008: Phase I study of the alpha specific PI3-Kinase inhibitor BYL719 and the poly (ADP-Ribose) polymerase (PARP) inhibitor olaparib in recurrent ovarian and breast cancer: Analysis of the dose escalation and ovarian cancer expansion cohort
Konstantinopoulos, P. A., Barry, W. T., Birrer, M. J., Westin, S. N., Farooq, S., Cadoo, K. A., Whalen, C., Luo, W., Liu, H., Aghajanian, C. A., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-ct008 · Cited by 5 · see citing works

Authors: Drew, Y., de Jonge, M., Hong, S. H., Park, Y. H., Wolfer, A., Brown, J., Ferguson, M., Gore, M. E., Alvarez, R. H., Gresty, C., Angell, H., Meyer, K., Learoyd, M., Tang, M., Lanasa, M., Herbolsheimer, P., & Domchek, S. M.
Affiliations: Newcastle University (GB)
The Catholic University of Korea Seoul St. Mary's Hospital (KR)
Samsung Medical Center (KR)
Centre Hospitalier Universitaire Vaudois (CH)
Beatson West of Scotland Cancer Centre (GB)
NHS Tayside (GB)
Royal Marsden Hospital (GB)
AstraZeneca (United Kingdom) (GB)
AstraZeneca (United States) (US)
University of Pennsylvania (US)
Corresponding author: Drew, Y.
ORCID: Drew, Y.
Hong, S.H.
Park, Y.H.
Wolfer, A.
Ferguson, M.
Gresty, C.
Angell, H.
Meyer, K.
Learoyd, M.
Tang, M.
Domchek, S.M.
Venue: Gynecologic Oncology
Publisher: Elsevier BV
Published: 2018-06
Volume: 149
Pages: 246-247
ISSN: 0090-8258 (ISSN-L)
DOI: 10.1016/j.ygyno.2018.04.555
OpenAlex: W2811158315
Cited by: 131
References: 0
Citations by year: 2026: 2 · 2025: 7 · 2024: 4 · 2023: 14 · 2022: 12 · 2021: 19 · 2020: 37 · 2019: 30 · 2018: 6
FWCI: 8.70
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Gynecologic Oncology (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
Keywords: olaparib, durvalumab, germline BRCA mutation, platinum-sensitive recurrent ovarian cancer, PARP inhibitors, PD-L1 inhibitors, combination therapy, maintenance therapy, treatment efficacy and safety

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated ( gBRCA m) platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cited by

Related

Record

About these checks